Literature DB >> 9294997

Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention.

D J Kereiakes1, T M Broderick, D D Whang, L Anderson, D Fye.   

Abstract

Serious hemorrhage and vascular complications after abciximab therapy are associated with elevated activated clotting time values. Our preliminary experience suggests that low-dose intravenous protamine administration is both safe and effective in reducing elevated in-laboratory activated clotting time values and the potential for serious hemorrhage in abciximab-treated patients.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9294997     DOI： 10.1016/s0002-9149(97)00437-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Antiplatelet therapy in interventional cardiology: II. Glycoprotein IIb/IIIa inhibitors.

Authors:  F H Jafary; C D Kimmelstiel
Journal:  J Thromb Thrombolysis       Date:  2000-02       Impact factor: 2.300

Review 2.  Managing adverse effects and drug-drug interactions of antiplatelet agents.

Authors:  Arun Kalyanasundaram; A Michael Lincoff
Journal:  Nat Rev Cardiol       Date:  2011-09-13       Impact factor: 32.419

Review 3.  A risk-benefit assessment of abciximab in angioplasty.

Authors:  N S Kleiman
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

4.  Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis.

Authors:  Giuseppe De Luca; Guido Parodi; David Antoniucci
Journal:  J Thromb Thrombolysis       Date:  2010-11       Impact factor: 2.300

Review 5.  Abciximab. An updated review of its use in ischaemic heart disease.

Authors:  R H Foster; L R Wiseman
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

6.  The use of protamine after radiofrequency catheter ablation: a pilot study.

Authors:  Aarti A Patel; Christopher A Clyne; Nickole N Henyan; C Michael White; Bryan F Zembrowski; Magdy Migeed; Ravi Yarlagadda; Jeffrey Kluger; Craig I Coleman
Journal:  J Interv Card Electrophysiol       Date:  2007-02-23       Impact factor: 1.759
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.